-- (--)

Trading Volume TOP20 | Google Tumbles 12% After Earnings, Recording Largest Single-Day Decline Since Listing; Eli Lilly Rises More Than 6% to New High, Upgrading Annual Guidance for Third Time This Year; Apple Breaks New High Against the Trend; Microsoft Plans to Raise $25 Billion in Debt

Eli Lilly's weight-loss drug performs strongly, driving record-high stock prices; Wall Street remains optimistic

Eli Lilly's stock price hits a new high, with a cumulative increase of nearly 60% in the past year

Eli Lilly’s Q3 revenue increases by 39% year-on-year, exceeding expectations; GLP-1 contributes over 60% of revenue, and for the third time this year, the full-year guidance has been raised

Eli Lilly’s Q3 revenue increases by 39% year-on-year, far exceeding expectations; GLP-1 contributes over 60% of revenue. Third time this year to raise full-year guidance.

Eli Lilly is about to release its financial report, what is the market focusing on?

The Alzheimer’s Disease Drug Discovery Foundation’s Diagnostic Accelerator authorizes the SpeechDx dataset to Eli Lilly to advance research on vocal biomarkers

US Stock Market Close | Tech Stocks Counterattack in the Late Session, NASDAQ Nearly Hits a Gain, Dow Jones Up More than 1%; Crypto Concepts Active, Circle Up More than 9%, Coinbase Up 6%; Eli Lilly Up More than 3% Again

Royal Bank of Canada maintains its rating of Eli Lilly as “outperforming the market,” with a target price of $1,500, and expects the company to raise its annual revenue guidance by about $2 billion

Eli Lilly stock: There may be a reason for taking profits before 2027